KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Gains from Sales and Divestitures (2016 - 2021)

Abbott Laboratories' Gains from Sales and Divestitures history spans 12 years, with the latest figure at $6.5 million for Q4 2021.

  • For Q4 2021, Gains from Sales and Divestitures fell 9.21% year-over-year to $6.5 million; the TTM value through Dec 2021 reached $6.5 million, down 9.21%, while the annual FY2021 figure was $6.5 million, 9.21% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2021 was $6.5 million at Abbott Laboratories, down from $7.2 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $7.8 million in Q4 2019 and bottomed at $6.5 million in Q4 2021.
  • The 5-year median for Gains from Sales and Divestitures is $7.5 million (2018), against an average of $7.3 million.
  • The largest annual shift saw Gains from Sales and Divestitures grew 29.29% in 2017 before it dropped 9.21% in 2021.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $7.6 million in 2017, then decreased by 0.42% to $7.5 million in 2018, then increased by 3.03% to $7.8 million in 2019, then dropped by 7.52% to $7.2 million in 2020, then dropped by 9.21% to $6.5 million in 2021.
  • Per Business Quant, the three most recent readings for ABT's Gains from Sales and Divestitures are $6.5 million (Q4 2021), $7.2 million (Q4 2020), and $7.8 million (Q4 2019).